10 terminated. 10 Phase 1, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Terminated 10 |
| Phase 2 | 10 | Terminated 10 |
Follow BioNTech SE: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy GEN1055, Pembrolizumab, Standard Chemotherapy - Malignant Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 21 | 2024-05-14 | 2026-08-11 |
| Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 1 | 2024-03-27 | 2025-10-31 |
| A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors GEN1042, Pembrolizumab, Radiotherapy - Non-CNS Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 13 | 2023-03-08 | 2026-08-12 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection | Phase 1 / Phase 2 | Terminated | Pfizer | 484 | 2023-01-25 | 2026-05-04 |
| A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy GEN1053 - Solid Tumor, Adult | Phase 1 / Phase 2 | Terminated | Genmab | 31 | 2022-10-04 | 2025-04-22 |
| Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors BNT142 - Solid Tumor | Phase 1 / Phase 2 | Terminated | BioNTech SE | 73 | 2022-03-22 | 2026-04-08 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors BNT141, Nab-paclitaxel, Gemcitabine - Solid Tumor, Gastric Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 13 | 2022-01-18 | 2024-10-02 |
| BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors BNT151 - Solid Tumor | Phase 1 / Phase 2 | Terminated | BioNTech SE | 49 | 2021-01-26 | 2025-07-02 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 BNT411, Atezolizumab, Carboplatin - Solid Tumor, Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 54 | 2020-06-19 | 2025-03-18 |
| PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) BNT112, Cemiplimab - Prostate Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 75 | 2019-12-19 | 2025-03-20 |
Pancreatic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Chickenpox (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Herpes Zoster (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Etoposide (1) · Gemcitabine (1) · Injections (1) · Radiotherapy (1) · Suspensions (1) · atezolizumab (1) · cemiplimab (1)
United States (9) · Spain (5) · United Kingdom (3) · Germany (2) · Canada (1) · France (1) · Hungary (1) · Singapore (1)
PMID 37592303, PMID 37860278, PMID 38776391
2023 (3), 2019 (2), 2018 (1)